- Home
- DCI vs KRYS Comparison
DCI vs KRYS Comparison
Compare DCI & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCI | KRYS |
|---|---|---|
| Founded | 1915 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 10.3B |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DCI | KRYS |
|---|---|---|
| Price | $88.34 | $369.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $99.00 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 780.2K | 331.4K |
| Earning Date | 06-02-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | ★ 2.75 | 1.83 |
| Revenue | ★ $2,844,900,000.00 | $389,130,000.00 |
| Revenue This Year | $4.58 | $38.74 |
| Revenue Next Year | $5.18 | $32.53 |
| P/E Ratio | ★ $32.39 | $204.58 |
| Revenue Growth | 4.05 | ★ 33.94 |
| 52 Week Low | $69.03 | $130.50 |
| 52 Week High | $112.84 | $382.54 |
Technical Indicators
Market Signals| Indicator | DCI | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 74.22 |
| Support Level | $88.50 | $246.17 |
| Resistance Level | $90.73 | N/A |
| Average True Range (ATR) | 1.87 | 13.79 |
| MACD | 0.39 | 3.15 |
| Stochastic Oscillator | 84.26 | 89.11 |
Price Performance
Historical ComparisonAbout DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.